Odonate Therapeutics announced that it has initiated CONTESSA 2, a multinational, multicenter, Phase 2 study of tesetaxel, Odonate’s investigational, orally administered taxane, in patients with locally advanced or metastatic breast cancer who have not previously received a taxane. CONTESSA 2 will investigate the combination of tesetaxel plus a reduced dose of capecitabine in approximately 125 patients with human epidermal growth factor receptor 2 negative, hormone receptor positive disease. The primary endpoint is objective response rate as assessed by an Independent Radiologic Review Committee.
https://thefly.com/landingPageNews.php?id=2874023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.